A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
Authors
Keywords
-
Journal
BMC CANCER
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-06
DOI
10.1186/s12885-022-09385-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
- (2022) Kazuki Takada et al. PLoS One
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- (2021) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of probiotics on the efficacy of anti‐PD ‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
- (2021) Kazuki Takada et al. INTERNATIONAL JOURNAL OF CANCER
- Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy
- (2021) K. Takada et al. ESMO Open
- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
- (2020) M. Chalabi et al. ANNALS OF ONCOLOGY
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
- (2020) MARTIN SVATON et al. ANTICANCER RESEARCH
- Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
- (2020) Sara Vieira-Silva et al. NATURE
- The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors
- (2020) Michael S. Oh et al. Clinical Lung Cancer
- Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
- (2020) Yusuke Tomita et al. Cancer Immunology Research
- Statins as anti-cancer agents in the era of precision medicine
- (2020) Joseph Longo et al. CLINICAL CANCER RESEARCH
- Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
- (2020) Janice J.N. Li et al. LUNG CANCER
- High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
- (2020) Luca Cantini et al. EUROPEAN JOURNAL OF CANCER
- Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
- (2020) Shinkichi Takamori et al. LUNG CANCER
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
- (2019) Xingzhe Ma et al. Cell Metabolism
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
- (2018) Keigo Kobayashi et al. Clinical Lung Cancer
- Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
- (2018) Daichi Fujimoto et al. LUNG CANCER
- Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
- (2018) Federica Iannelli et al. Recent Patents on Anti-Cancer Drug Discovery
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
- (2018) Yun Xia et al. CELL
- Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
- (2018) Mohammed A. M. Farooqi et al. PLoS One
- The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials
- (2018) Hyun Jang et al. Journal of Clinical Medicine
- Statin use and all-cause and cancer mortality: BioBank Japan cohort
- (2017) Hiroshi Yokomichi et al. JOURNAL OF EPIDEMIOLOGY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
- (2017) Elizabeth Dudnik et al. LUNG CANCER
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Statin use and all-cancer survival: prospective results from the Women’s Health Initiative
- (2016) Ange Wang et al. BRITISH JOURNAL OF CANCER
- Statins Are Associated With Reduced Mortality in Multiple Myeloma
- (2016) Kristen Marie Sanfilippo et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
- (2016) Antonio Marchetti et al. Journal of Thoracic Oncology
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease
- (2015) Sripal Bangalore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic control of YAP and TAZ by the mevalonate pathway
- (2014) Giovanni Sorrentino et al. NATURE CELL BIOLOGY
- Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis
- (2013) H. S. Park et al. ANNALS OF ONCOLOGY
- p53 and cancer stem cells: The mevalonate connexion
- (2012) Christophe Ginestier et al. CELL CYCLE
- Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
- (2012) M. Thurnher et al. CLINICAL CANCER RESEARCH
- Statin Use and Reduced Cancer-Related Mortality
- (2012) Sune F. Nielsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statins and cancer: A systematic review and meta-analysis
- (2008) Jaana Kuoppala et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now